German Hodgkin’s Lymphoma Study Group

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Chemotherapy-treated patients with advanced Hodgkin’s disease (HD) differ considerably in acute hematotoxicity. Hematotoxicity may be indicative of pharmacological and metabolic heterogeneity. We hypothesized that low hematotoxicity might correlate with reduced systemic dose and thus reduced disease control. A total of 266 patients with advanced HD treated(More)
  • 1